Brinton, Eliot A.

Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins

Bays, H. E., Baum, S. J., Brinton, E. A., Plutzky, J., Hanselman, J. C., Teng, R., & Ballantyne, C. M. (2021) · American Journal of Preventive Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 25

REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results

Olshansky, B., Bhatt, D. L., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle Jr, R. T., Juliano, R. A., Jiao, L., et al. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 25

Lipid effects of icosapent ethyl in women with diabetes mellitus and persistent high triglycerides on statin treatment: ANCHOR trial subanalysis

Brinton, E. A., Ballantyne, C. M., Guyton, J. R., Philip, S., Doyle, R. T., Juliano, R. A., & Mosca, L. (2018) · Journal of Women's Health

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 13

COST-EFFECTIVENESS OF ICOSAPENT ETHYL IN US REDUCE-IT PATIENTS

Weintraub, W. S., Bhatt, D., Zhang, Z., Zhang, C., Sarahfaye, D., Boden, W. E., Steg, P. G., Miller, M., Brinton, E., King, J., et al. (2020) · Journal of the American College of Cardiology

Fatty Acid Research and HealthHealth Systems, Economic Evaluations, Quality of Life

Cited by 13

Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn

Miller, M., Bhatt, D. L., Brinton, E. A., Jacobson, T. A., Steg, P. G., Pineda, A. L., Ketchum, S. B., Doyle, R. T., Tardif, J.-C., & Ballantyne, C. M. (2023) · European Heart Journal Open

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 11

Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT

Szarek, M., Bhatt, D., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Tardif, J. C., Ballantyne, C. M., Ketchum, S. B., Pineda, A. L., et al. (2023) · European Heart Journal

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 9

Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM

Miller, M., Bhatt, D. L., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Pineda, A. L., Tardif, J.-C., & Ballantyne, C. M. (2026) · American Journal of Preventive Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 0